ARTELO BIOSCIENCES, INC.
ARTLNasdaq
$1.15
↑ +0.9%Jul 17 close · end-of-day
Price
1Y↓ -97.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$849,850.00
Enterprise Value
-$9.4M
P/E
—
P/S
—
P/B
0.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$13.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-201.8%
ROIC
—
Debt / Equity
—
Net Cash
$10.3M
Return 1Y
-97.5%
Company profile
Artelo Biosciences, Inc. focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer. ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD.
- CEO
- Gregory D. Gorgas
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 5
- Headquarters
- California
- Website
- artelobio.com
Earnings
ARTL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$4.00↓ -68.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Operating income | -$4.7M | -$7.4M | -$9.4M | -$10.3M | -$9.9M | -$10.1M | -$11.4M |
| Net income | -$4.7M | -$7.4M | -$9.4M | -$10.1M | -$9.3M | -$9.8M | -$12.9M |
| Diluted EPS | — | — | — | — | -$18.80 | -$54.89 | -$37.75 |
| Operating cash flow | -$4.3M | -$6.1M | — | -$8.0M | -$8.2M | -$8.3M | -$8.5M |
| Free cash flow | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.5M | -$1.2M | -$3.8M | -$2.4M | -$3.1M | -$3.1M | -$2.8M | -$2.7M |
| Net income | -$2.4M | -$1.1M | -$3.8M | -$2.4M | -$3.2M | -$3.1M | -$4.2M | -$3.0M |
| Diluted EPS | -$4.52 | -$2.10 | -$43.61 | -$12.55 | -$5.61 | -$3.97 | -$15.62 | -$4.00 |
| Operating cash flow | -$2.1M | -$778,000.00 | -$2.6M | -$1.6M | -$514,000.00 | -$3.5M | -$2.9M | -$1.2M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.